Free Trial
NASDAQ:AVTE

Aerovate Therapeutics Q3 2024 Earnings Report

Aerovate Therapeutics logo
$12.48 +2.48 (+24.80%)
As of 05/2/2025

Aerovate Therapeutics EPS Results

Actual EPS
-$19.60
Consensus EPS
-$20.65
Beat/Miss
Beat by +$1.05
One Year Ago EPS
N/A

Aerovate Therapeutics Revenue Results

Actual Revenue
N/A
Expected Revenue
N/A
Beat/Miss
N/A
YoY Revenue Growth
N/A

Aerovate Therapeutics Announcement Details

Quarter
Q3 2024
Time
After Market Closes
Conference Call Date
Tuesday, November 12, 2024
Conference Call Time
4:00PM ET

Upcoming Earnings

Aerovate Therapeutics' Q2 2025 earnings is scheduled for Monday, May 12, 2025

Earnings Documents

Aerovate Therapeutics Earnings Headlines

Think NVDA’s run was epic? You ain’t seen nothin’ yet
Ask most investors and they’ll probably tell you Nvidia is the undisputed AI stock of the decade. In 2023, it surged 239%. And in 2024, it soared another 171% on the year… But what if I told you there was a way to target those types of “peak Nvidia” profit opportunities in 24 hours or less?
See More Aerovate Therapeutics Headlines
Get Earnings Announcements in your inbox

Want to stay updated on the latest earnings announcements and upcoming reports for companies like Aerovate Therapeutics? Sign up for Earnings360's daily newsletter to receive timely earnings updates on Aerovate Therapeutics and other key companies, straight to your email.

About Aerovate Therapeutics

Aerovate Therapeutics (NASDAQ:AVTE), a clinical-stage biopharmaceutical company, develops drugs that enhance the lives of patients with rare cardiopulmonary diseases in the United States. It focuses on advancing AV-101, a dry powder inhaled formulation of imatinib for the treatment of pulmonary arterial hypertension, which is in Phase 2b/Phase 3 trial. The company was incorporated in 2018 and is headquartered in Waltham, Massachusetts.

View Aerovate Therapeutics Profile

More Earnings Resources from MarketBeat